Deal Roundup: BC sells Synthon stake to Goldman PE arm, valuing company at about €2bn, Stonepeak to buy Forgital from Carlyle

Goldman Sachs Alternatives' PE arm has agreed to pick up a majority stake in Synthon from BC Partners in a deal believed to value the international pharmaceutical business at about €2bn.